H.D. Smith elevates sales, purchasing leaders
SPRINGFIELD, Ill. Pharmacy wholesaler H.D. Smith has promoted two veteran executives in a continuing bid to strengthen its senior management ranks and boost its growth potential.
The latest moves include the promotion of Jeff Greer to VP sales and Bob Dynek Jr. to VP purchasing and trade relations.Greer, who joined the company in 2005 after long service with drug wholesale giant AmerisourceBergen, will lead an effort by H.D. Smith to expand into new service sectors. Dynek, an 11-year company veteran whose previous career included stints with General Drug Co., Foxmeyer Corp. and Louis Zahn Drug Co., will will have primary responsibility for purchasing and managing inventory service levels across all business segments.
“Moving Jeff and Bob into corporate headquarters will take full advantage of growth potential for the company,” said Dale Smith, chairman and CEO. “Together, they bring more than 50 years of expertise in pharmacy distribution and will be influential in helping us realize our goal of becoming the preferred pharmaceutical wholesaler nationwide.”
Experts discuss medication adherence
WASHINGTON Poor adherence to medication regimens could counteract the benefits of healthcare reform, a panel of experts concluded Wednesday.
The panel — which brings together experts from GlaxoSmithKline, the National Association of Chain Drug Stores Foundation, the National Consumer’s League and the Pharmaceutical Research and Manufacturers of America — hopes to open a dialogue about medication adherence with between experts from the health, medical, insurance, business, employer, academic and government sectors.
“To date, medication adherence hasn’t been a prominent part of the debate,” conference moderator and founding editor of the journal Health Affairs John Iglehart said in a statement. “But no matter what shape health reform takes, it will ultimately be more successful if it supports the education and motivation of patients to properly follow their medication regimens.”
Participants in the panel will receive briefings on two new research efforts on medication adherence conducted by Avalere Health and the RAND Corp., respectively, using findings from the studies to guide the creation of policy and public education recommendations.
As many as 80% of patients may not be adhering to their medication regimens, according to research, resulting in adverse consequences and draining $100 billion to $300 billion from the healthcare system every year.
MiddleBrook Pharmaceuticals develops copay program for Moxatag
WESTLAKE, Texas A company making a long-acting formulation of a common antibiotic has announced a program to minimize the drug’s cost to consumers.
MiddleBrook Pharmaceuticals announced Wednesday a $20 maximum copay program for Moxatag (amoxicillin) extended-release tablets in the 775 mg strength, designed to keep the drug’s cost to patients at $20 or less. The company said it will field 300 representatives and district managers to begin supplying physicians with voucher cards for the program.
“In this tough economy, we recognize the need to improve Moxatag’s affordability to the patient,” MiddleBrook president and CEO John Thievon said in a statement. “This $20 maximum copay program will replace our current $15 point-of-sale copay check program, which has been in place since Moxatag’s launch.”